|Bid||7.00 x 1000|
|Ask||9.35 x 900|
|Day's Range||7.21 - 8.11|
|52 Week Range||6.21 - 15.05|
|Beta (3Y Monthly)||2.27|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 1, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.83|
Cytokinetics, Incorporated (CYTK) today announced that it is scheduled to report third quarter results on November 1, 2018 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The conference call will be simultaneously webcast and can be accessed from the homepage and in the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com.
Cytokinetics, Incorporated (CYTK) plans to present an expansion of its development pipeline with the progression of two additional cardiac muscle directed drug candidates towards first-in-human clinical trials, at an R&D Day today in New York. The first, a novel cardiac troponin activator, discovered under its joint research program with Amgen, was the subject of an Investigational New Drug Application (IND) that Amgen recently filed with the Food & Drug Administration (FDA).
NEW YORK, Oct. 09, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
As we step into the final quarter of 2018, biotech stocks have recorded double-digit gains for the year-to-date period. Will the run up continue? Stay tuned to the following events of the upcoming week. ...
Cytokinetics, Incorporated (Nasdaq: CYTK, “Cytokinetics”) and Astellas Pharma Inc. (TSE: 4503, “Astellas”) today provided an update for their collaborative skeletal muscle program, including clinical trial updates for reldesemtiv in neuromuscular and non-neuromuscular conditions. In addition to reldesemtiv, the companies are advancing another fast skeletal muscle troponin activator (FSTA) into Investigational New Drug (IND)-enabling studies and continuing their joint research program through 2019. Cytokinetics has been developing reldesemtiv as a potential treatment for people with Spinal Muscular Atrophy (SMA), Amyotrophic Lateral Sclerosis (ALS), and other debilitating neuromuscular diseases and conditions associated with skeletal muscle weakness and/or fatigue.
Cytokinetics, Incorporated (CYTK), today announced that it will host an R&D Day on Tuesday, October 16, 2018 from 8:30 AM to 12:30 PM ET at the Parker New York Hotel in New York City. Members of Cytokinetics’ senior management will be joined by expert clinicians to provide new updates to the pipeline and review current clinical programs.
If you’re interested in Cytokinetics Incorporated (NASDAQ:CYTK), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact Read More...
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2018-- Cytokinetics, Inc. today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the Cantor Fitzgerald ...
Cantor Fitzgerald has high hopes for patients with rare and orphan diseases. “We believe that biotech has entered a golden age of innovation and productivity across many therapeutic areas,” the firm said ...
Biotech were trending mostly sideways in the week ending Sept. 14 after posting weekly gains in the previous two weeks. Notwithstanding the overall muted sentiment, there was some activity in reaction ...
Cytokinetics, Inc. (CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 16th Annual Morgan Stanley Global Healthcare Conference on Wednesday, September 12, 2018 at 11:40 AM ET at the Grant Hyatt in New York City. The webcast replay of the presentation will be archived on the Presentations page within the Investors & Media section of Cytokinetics’ website for 90 days following the conclusion of the event. Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.
Cytokinetics, Incorporated (CYTK) today announced that The ALS Association Golden West Chapter is the inaugural recipient of the Cytokinetics Communications Fellowship, an annual grant from the company intended to support increased capacity and community engagement for nonprofit organizations. “As a longstanding partner of the disease and patient advocacy community, we recognized a need for organizations to expand the scope of their communications to support families with rare diseases of muscle dysfunction and we sought an opportunity to close that gap,” said Diane Weiser, Cytokinetics’ Vice President of Corporate Communications and Investor Relations. “We are extremely grateful to Cytokinetics and honored to receive this unique grant,” said Fred Fisher, MSW, President and CEO of The ALS Association Golden West Chapter.
Biopharma Cytokinetics Inc. (NASDAQ: CYTK ) announced a delay in drug studies during its earnings call Thursday, prompting a downgrade by Morgan Stanley. The Analysts Morgan Stanley's Matthew Harrison ...
NEW YORK, Aug. 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of US ...
The South San Francisco, California-based company said it had a loss of 51 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Phase 2 Study of Reldesemtiv in Patients with SMA Showed Potentially Clinically Meaningful Effects on Six Minute Walk Distance and Maximal Expiratory Pressure. Results from Phase 2 Clinical Trial of Reldesemtiv ...
Cytokinetics (NASDASQ:CYTK) looks to turn around their fortunes following last year’s unsuccessful readout of Tirasemtiv in ALS. The company’s follow on asset Reldesemtiv, is built on the same mechanism but looks to resolve the dropout issue. Further, the drug seems to be more potent than its predecessor, which may help amplify the signal we saw in respiratory function.
Looking to add potential meaningful upside to your portfolio, but unsure where to start? Stocks such as Globant and Cytokinetics are considered to be high growth in terms of howRead More...
Investors in Cytokinetics (CYTK) need to pay close attention to the stock based on moves in the options market lately.